Increasing Prevalence Of Smoking Is Fueling The Market Due To Rising Respiratory Health Complications Is Supporting Development Across The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market During The 2026–2030 Period?

The asthma and chronic obstructive pulmonary disease (copd) drugs market size has shown robust expansion in recent years. It is projected to expand from $35.66 billion in 2025 to $39.07 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. The expansion observed in the historic period can be attributed to several factors, including rising smoking prevalence, urban air pollution, advancements in hospital-based respiratory care, the adoption of inhaler technology, and an increase in asthma diagnosis.

The asthma and chronic obstructive pulmonary disease (COPD) drugs market size is projected to undergo significant expansion in the coming years. It is foreseen to increase to $55.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. The drivers behind this growth within the forecast period comprise biologic drug innovation, the aging population, worsening air quality, advancements in personalized respiratory medicine, and the emergence of homecare respiratory solutions. Prominent trends for the forecast period involve an escalated utilization of combination inhaler therapies, the increasing embrace of long-acting bronchodilators, the widespread application of biologic therapies for severe asthma, a move towards managing respiratory conditions in home settings, and a heightened demand for generic inhalation drugs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

Which Core Factors Are Supporting The Expansion Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The rising incidence of smoking is projected to fuel the expansion of the asthma and COPD drugs market in the future. Smoking involves the practice of using tobacco by inhaling its smoke, a habit known to cause severe health problems like lung cancer and heart disease. This growing prevalence of smoking primarily stems from social influence, as peer pressure, societal norms, and social settings often prompt individuals to begin and persist with smoking. Medications for asthma and chronic obstructive pulmonary disease (COPD) work to lessen the respiratory harm from smoking by decreasing inflammation, relaxing airway muscles, and enhancing airflow, consequently easing symptoms and boosting lung function. For instance, in 2024, data from a study by the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, on youth smoking trends revealed a significant increase in smoking rates, climbing from 22.5% of respondents in 2022 to 40.1% in 2024. Consequently, the expanding prevalence of smoking is accelerating the growth of the asthma and COPD drugs market.

Which Segment Divisions Form The Structure Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The asthma and chronic obstructive pulmonary disease (copd) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

What Trends Are Shaping The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Structure?

Leading companies in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are prioritizing the integration of innovative drug-combination therapies, such as short-acting beta-agonist (SABA) and inhaled corticosteroid (ICS) rescue inhalers. This strategic focus aims to enhance benefits like the prevention of severe asthma attacks, better inflammation control, and more effective overall disease management. A SABA–ICS rescue inhaler combines a short-acting beta-agonist, which quickly relaxes airway muscles for symptom relief, with an inhaled corticosteroid, which reduces underlying airway inflammation, providing dual capabilities of immediate symptom alleviation alongside anti-inflammatory action. For instance, in January 2024, AstraZeneca, a UK–based biopharmaceutical company, launched AIRSUPRA (albuterol/budesonide) in the US. This fixed-dose SABA-ICS rescue inhaler is designed to treat asthma symptoms and help prevent sudden severe breathing problems, featuring its dual-component formulation delivered via pressurised metered-dose inhaler (pMDI) Aerosphere technology. AIRSUPRA improves acute symptom relief while simultaneously addressing airway inflammation, thereby decreasing the risk of severe asthma exacerbations and enhancing overall asthma control.

Who Are The Companies Shaping The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Landscape?

Major companies operating in the asthma and chronic obstructive pulmonary disease (copd) drugs market are Sun Pharmaceutical Industries Ltd., Viatris Inc., Hikma Pharmaceuticals PLC, Orion Corporation, Bausch Health Companies Inc., Kyorin Pharmaceutical Co. Ltd., Sandoz International GmbH, Mundipharma International Ltd., Ferrer Internacional S.A., Neopharm Group, Covis Pharma Group, Almirall S.A., Menarini Group, Cipla Health Ltd., Indoco Remedies Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Wockhardt Ltd., Ajanta Pharma Ltd., Emcure Pharmaceuticals Ltd., Abbott Laboratories, Endo International plc, Takeda Pharmaceutical Company Ltd.

Access The Complete Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

Which Regional Market Leads The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

North America was the largest region in the asthma and COPD drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (copd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

Browse Through More Reports Similar to the Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2026, By The Business Research Company

Anti Asthmatics And Copd Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Digital Dose Inhalers Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-dose-inhalers-global-market-report

Inhaled Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info